Scholar Rock's niche

Scholar Rock LLC, which attracted $20 million in investments and a big pharma deal before releasing any data, is now providing evidence that its niche modulator compounds can in fact specifically target transforming growth factor β1 (TGFβ1) and other growth factors in disease tissues with a unique mechanism.

At the Federation of American Societies for Experimental Biology (FASEB) scientific research conference on TGFβ this summer, the company presented data on its first antibody, showing it specifically binds and activates latent TGFβ1 to modulate T cell activity. ...